NCT05914376View on ClinicalTrials.gov

Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 5, 2023

Primary Completion Date

October 11, 2025

Study Completion Date

November 30, 2025

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL

Recombinant human IL-21-expressing oncolytic vaccinia virus injection

hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.

Trial Locations (2)

Unknown

Zhejiang People's Hospital, Hangzhou

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Hangzhou Converd Co., Ltd.

INDUSTRY